Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies
Background: Chronic hepatitis C virus (HCV) infection is considered as one of the leading causes of liver disease in thalassemic patients in Iran. Over 40% of the mortality in these patients is related to HCV. Objectives: The present study aimed at estimating HCV prevalence in thalassemic patients i...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Journal of Virus Eradication |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020314552 |
id |
doaj-e6add36e06bf431e97c84e7f78f3c586 |
---|---|
record_format |
Article |
spelling |
doaj-e6add36e06bf431e97c84e7f78f3c5862021-05-05T04:07:28ZengElsevierJournal of Virus Eradication2055-66402020-09-0163100006Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategiesMeisam Moghimbeygi0Seyed Moayed Alavian1Department of Mathematics, Faculty of Mathematics and Computer Science, Kharazmi University, Tehran, Iran; Corresponding author.Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IranBackground: Chronic hepatitis C virus (HCV) infection is considered as one of the leading causes of liver disease in thalassemic patients in Iran. Over 40% of the mortality in these patients is related to HCV. Objectives: The present study aimed at estimating HCV prevalence in thalassemic patients in Iran and to determine the number of infections until eradication is achieved. Methods: A meta-analysis approach was used to estimate the number of HCV-infected thalassemic patients in the country. The prevalence rate was measured using a modeling approach to predict the number of cases until eradication using several scenarios in terms of testing and treatment, in particular the use of direct acting antiviral drugs (DAAs). Results: With the advent of DAAs with a high rate of treatment success, HCV could be eradicated earlier than originally thought among this group of patients. Based on previous predictions the number of HCV-infected thalassemic patients would have been below 66 by 2020. However, according to our predictions, the number will be less than 10 when using DAAs. Conclusion: We believe that HCV eradication can be achieved in thalassemic patients with an increased life expectancy by funding DAA-based new treatment strategies. This has been exemplified in Alborz, Lorestan, and South Khorasan provinces with HCV eradication in this group of patients.http://www.sciencedirect.com/science/article/pii/S2055664020314552Hepatitis CThalassemiaMeta-analysisSystematic reviewPrevalence |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Meisam Moghimbeygi Seyed Moayed Alavian |
spellingShingle |
Meisam Moghimbeygi Seyed Moayed Alavian Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies Journal of Virus Eradication Hepatitis C Thalassemia Meta-analysis Systematic review Prevalence |
author_facet |
Meisam Moghimbeygi Seyed Moayed Alavian |
author_sort |
Meisam Moghimbeygi |
title |
Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies |
title_short |
Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies |
title_full |
Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies |
title_fullStr |
Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies |
title_full_unstemmed |
Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies |
title_sort |
eradication of hepatitis c virus infection in thalassemia patients in iran using various treatment strategies |
publisher |
Elsevier |
series |
Journal of Virus Eradication |
issn |
2055-6640 |
publishDate |
2020-09-01 |
description |
Background: Chronic hepatitis C virus (HCV) infection is considered as one of the leading causes of liver disease in thalassemic patients in Iran. Over 40% of the mortality in these patients is related to HCV. Objectives: The present study aimed at estimating HCV prevalence in thalassemic patients in Iran and to determine the number of infections until eradication is achieved. Methods: A meta-analysis approach was used to estimate the number of HCV-infected thalassemic patients in the country. The prevalence rate was measured using a modeling approach to predict the number of cases until eradication using several scenarios in terms of testing and treatment, in particular the use of direct acting antiviral drugs (DAAs). Results: With the advent of DAAs with a high rate of treatment success, HCV could be eradicated earlier than originally thought among this group of patients. Based on previous predictions the number of HCV-infected thalassemic patients would have been below 66 by 2020. However, according to our predictions, the number will be less than 10 when using DAAs. Conclusion: We believe that HCV eradication can be achieved in thalassemic patients with an increased life expectancy by funding DAA-based new treatment strategies. This has been exemplified in Alborz, Lorestan, and South Khorasan provinces with HCV eradication in this group of patients. |
topic |
Hepatitis C Thalassemia Meta-analysis Systematic review Prevalence |
url |
http://www.sciencedirect.com/science/article/pii/S2055664020314552 |
work_keys_str_mv |
AT meisammoghimbeygi eradicationofhepatitiscvirusinfectioninthalassemiapatientsiniranusingvarioustreatmentstrategies AT seyedmoayedalavian eradicationofhepatitiscvirusinfectioninthalassemiapatientsiniranusingvarioustreatmentstrategies |
_version_ |
1721475651128524800 |